Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park J.-Y. | - |
dc.contributor.author | Kim K.-A. | - |
dc.contributor.author | Shin J.-G. | - |
dc.contributor.author | Lee K.Y. | - |
dc.date.available | 2020-11-03T17:51:43Z | - |
dc.date.issued | 2004 | - |
dc.identifier.issn | 0306-5251 | - |
dc.identifier.issn | 1365-2125 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/20862 | - |
dc.description.abstract | Aims: Fungal infection is a significant comorbidity in patients with diabetes mellitus, and ketoconazole, an antifungal agent, causes a number of drug interactions with coadministered drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic drug, mainly metabolized by CYP2C8 and to a lesser extent CYP2C9. We investigated the possible effect of ketoconazole on the pharmacokinetics of rosiglitazone in humans. Methods: Ten healthy Korean male volunteers were treated twice daily for 5 days with 200 mg ketoconazole or with placebo, using a randomized, open-label, two-way crossover study. On day 5, a single dose of 8 mg rosiglitazone was administered orally, and plasma rosiglitazone concentrations were measured. Results: Ketoconazole increased the mean area under the plasma concentration-time curve for rosiglitazone by 47% [P = 0.0003; 95% confidence interval (CI) 23, 70] and the mean elimination half-life from 3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4). The peak plasma concentration of rosiglitazone was increased by ketoconazole treatment by 17% (P = 0.03; 95% CI 5, 29). The apparent oral clearance of rosiglitazone decreased by 28% after ketoconazole treatment (P = 0.0005; 95% CI 18, 38). Conclusions: This study revealed that ketoconazole affected the disposition of rosiglitazone in humans, probably by the inhibition of CYP2C8 and CYP2C9, leading to increasing rosiglitazone concentrations that could increase the efficacy of rosiglitazone or its adverse events. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/j.1365-2125.2004.02161.x | - |
dc.identifier.scopusid | 2-s2.0-4744348757 | - |
dc.identifier.bibliographicCitation | British Journal of Clinical Pharmacology, v.58, no.4, pp 397 - 402 | - |
dc.citation.title | British Journal of Clinical Pharmacology | - |
dc.citation.volume | 58 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 397 | - |
dc.citation.endPage | 402 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | cytochrome P450 2C8 | - |
dc.subject.keywordPlus | cytochrome P450 2C9 | - |
dc.subject.keywordPlus | gemfibrozil | - |
dc.subject.keywordPlus | ketoconazole | - |
dc.subject.keywordPlus | pioglitazone | - |
dc.subject.keywordPlus | placebo | - |
dc.subject.keywordPlus | rosiglitazone | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | anasarca | - |
dc.subject.keywordPlus | antifungal activity | - |
dc.subject.keywordPlus | area under the curve | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | comorbidity | - |
dc.subject.keywordPlus | concentration response | - |
dc.subject.keywordPlus | confidence interval | - |
dc.subject.keywordPlus | controlled clinical trial | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | crossover procedure | - |
dc.subject.keywordPlus | diabetes mellitus | - |
dc.subject.keywordPlus | dose time effect relation | - |
dc.subject.keywordPlus | drug blood level | - |
dc.subject.keywordPlus | drug clearance | - |
dc.subject.keywordPlus | drug cross reactivity | - |
dc.subject.keywordPlus | drug disposition | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | enzyme inhibition | - |
dc.subject.keywordPlus | glucose metabolism | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human experiment | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | liver toxicity | - |
dc.subject.keywordPlus | lung edema | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | mycosis | - |
dc.subject.keywordPlus | normal human | - |
dc.subject.keywordPlus | open study | - |
dc.subject.keywordPlus | peripheral edema | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | side effect | - |
dc.subject.keywordPlus | single drug dose | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Antifungal Agents | - |
dc.subject.keywordPlus | Cross-Over Studies | - |
dc.subject.keywordPlus | Drug Interactions | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Hypoglycemic Agents | - |
dc.subject.keywordPlus | Ketoconazole | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Thiazolidinediones | - |
dc.subject.keywordAuthor | CYP2C8 | - |
dc.subject.keywordAuthor | Drug interaction | - |
dc.subject.keywordAuthor | Ketoconazole | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
dc.subject.keywordAuthor | Rosiglitazone | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.